Corporate Overview

Our focus on improving patient outcomes today while driving the development of tomorrow’s next-generation medical technology is what brings our mission to life. From pioneering beginnings to a promising pipeline, at Biosensors our success is due to our focus on research and development, clinical excellence and our talented team.

Through our high quality medical devices, we impact the lives we touch, and we are committed to continue investing in and developing pioneering medical technology, pharmacological research, and engineering new medical devices that will further benefit our patients. This will create the greatest possible patient outcomes, and provide value to our stakeholders including physicians, shareholders and employees.

Since 1990, we have been developing and marketing critical care catheter systems and related devices used during heart surgery and intensive care treatment. Always seeking to be at the forefront of product innovation, we entered the interventional cardiology market in 2000 with our proprietary coronary stent and accompanying stent delivery system. In the same year, we further expanded our product line to include angioplasty balloons and catheters.

Most recently, we made our entry into the $6 billion global drug-eluting stent market with the introduction of BioMatrix™ our unique abluminal drug-eluting stent system with biodegradable coating and received the CE Mark regulatory approval in January 2008.

Our abluminal drug-eluting stent system is a unique combination of our proprietary anti-restenotic Biolimus A9™ (BA9™) drug and biodegradable PLA polymer. Together with an advanced, highly flexible stent platform designed for enhanced deliverability, it offers a true next-generation solution for patients everywhere.